Old news. This is included in the Clinical Trial website information. A P2 trial with 40 participants. IMO another trial that will last years and won't result in an approval. SNAFU.
”…"We are thrilled to partner with Anavex in this very important trial," said Matt Bevin, CEO at Cognision. "Our advanced EEG/ERP technology will provide early insights on the neural response to ANAVEX®3-71 in individuals with schizophrenia, possibly paving the way for more effective and targeted therapeutic interventions for this very vulnerable population."…”
Good Ole Bill, Cognision is a member of the Anavex Consortium that includes Merck, Takeda, Lundbeck and Alkemes along with Sage Therapeutics and Cadent Therapeutics.